MEAI Compound Shows Early Promise in Phase I/IIa Alcohol Use Disorder Trial
Clearmind Medicine's CMND-100, a non-hallucinogenic MEAI-based compound, is advancing through a first-in-human Phase I/…
Clearmind Medicine's CMND-100, a non-hallucinogenic MEAI-based compound, is advancing through a first-in-human Phase I/…
NuCicer's Nuchi delivers 50% more protein and 25% less fat than conventional chickpeas, addressing consumer demand for …
MycoTechnology and Adorvia partner to deliver clean-label sweetening solutions that reduce sugar intake while maintaini…
ADM and EVERY Company launch commercial OvoPro™ production, delivering clean-label, complete protein with superior amin…
Hofseth BioCare's capital raise will boost production of marine-derived proteins and omega-3 oils for functional foods …
Machine learning platforms help manufacturers compress reformulation cycles for reduced-sugar and functional candy—meet…
Glucose Health, Inc. says accelerating GlucoDown velocity at two top national drug store chains is driving measurable y…
Only 15% of CTD-ILD patients achieve drug-free remission, fueling interest in Bristol Myers Squibb's zola-cel, GSK's Be…
Accomplished health care leader brings decades of experience in systems transformation, patient and family engagement, …
New NASM data reveals 73% of personal trainers are fielding client inquiries regarding GLP-1 therapies; updated course …
The analysis explores how AI-driven innovations are transforming skin disease detection, treatment planning and aesthet…
Stop & Shop Kicks Off Summer Grilling with Buy One, Get One Free Father’s Day Deal on Grass-Fed Steak